Browsing Barts Cancer Institute by Subject "acute myeloid leukemia"
Now showing items 1-1 of 1
-
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
(Rockefeller University Press, 2019-03-19)Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the ...